混合扩散模型用于稳定,亲和力驱动,受体意识的生成.
Vishva Saravanan R1, Soham Choudhuri1, Bhaswar Ghosh1
1Center for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad 500032, India.
Journal of chemical information and modeling
|August 28, 2024
概括
我们开发了HYDRA,这是一种混合深度学习模型,用于设计治疗性. 这种人工智能方法通过向特定受体来增强类药物开发,为疟疾等疾病提供新的治疗方法.
科学领域:
- 生物技术和人工智能在药物发现中的作用
- 计算化学和生物信息学
- 治疗性体设计 治疗性体设计
背景情况:
- 与小分子相比,可以提供向治疗,副作用较少,但在生物可用性和降解方面面临挑战.
- 深度学习的进步为创新的设计提供了机会.
- 针对特定的蛋白质,如Plasmodium falciparum*红细胞膜蛋白1 (PfEMP1) 中的蛋白质,对于疾病治疗至关重要.
研究的目的:
- 介绍HYDRA,一种新的混合深度学习方法,用于治疗的新设计.
- 为了证明HYDRA在设计针对特定目标受体的结剂方面的能力.
- 将HYDRA应用于设计针对疟疾相关的PfEMP1蛋白质的.
主要方法:
- 开发HYDRA,一种混合深度学习模型,集成扩散模型用于分布建模.
- 结合扩散模型与结合亲和力最大化算法用于类设计.
- 在目标受体结合部位上生成条件,以实现精确的向.
主要成果:
- 通过使用HYDRA方法成功设计了治疗性.
- 证明了该模型能够产生类向受体上的特定结合位点的能力.
- 应用HYDRA来设计针对PfEMP1的,这是疟疾病原发生的关键蛋白质.
结论:
- 海德拉代表了一种有前途的人工智能驱动的策略,用于治疗性的设计.
- 这种方法促进了针对疟疾等疾病的向类疗法的开发.
- 这种方法有可能推动药物发现,不仅仅是疟疾,还包括其他疾病.
更多相关视频
13:49Semi-automated Biopanning of Bacterial Display Libraries for Peptide Affinity Reagent Discovery and Analysis of Resulting Isolates
Published on: December 6, 2017
11.4K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.0K
相关概念视频
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
3.6K
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
3.6K
Protein Diffusion in the Membrane
4.3K
Proteins show rotational as well as lateral diffusion across the membrane. The lateral diffusion of proteins was confirmed through the cell fusion experiment where mouse and human cells were fused, resulting in hybrid cells. When the human and mouse cells fused, the specific membrane proteins on human and mouse cells were marked with the red and green-fluorescent markers, respectively. Initially, the red and green fluorescence was located on the respective hemisphere of the cell. As time...
4.3K
